Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway

Yuan,Sujuan; Qiao,Tiankui; Li,Xuan; Zhuang,Xibing; Chen,Wei; Chen,Xue; Zhang,Qi

doi:10.3892/ol.2018.7916

Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway

Authors:
- Sujuan Yuan
- Tiankui Qiao
- Xuan Li
- Xibing Zhuang
- Wei Chen
- Xue Chen
- Qi Zhang
View Affiliations

Affiliations: Department of Oncology, Jinshan Hospital, Shanghai Medical College, Fudan University, Shanghai 201508, P.R. China, Department of Radiology, Shanghai Cancer Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
Published online on: January 31, 2018 https://doi.org/10.3892/ol.2018.7916
Pages: 5271-5279

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Unmethylated cytosine-phosphorothioate-guanine (CpG)-containing oligodeoxynucleotides (ODNs) are synthetic DNA sequences that mimic bacterial DNA, and are known to serve as ligands for Toll‑like receptor 9 (TLR9). The interaction between a CpG ODNs with TLR9 activates the complex downstream cascade that contributes to exerting its function. In the present study, the results of clonogenic assays demonstrated that the activation of TLR9 by CpG ODNs significantly increased the radiosensitivity of A549 lung cancer cells, with a sensitivity enhancement ratio (SER) of 1.28. When the expression of TLR9 was effectively silenced, CpG ODNs used alone were identified to produce SERs as low as 1.01. Flow cytometry demonstrated that the interaction between TLR9 and CpG ODN 7909 alone did not significantly affect the rate of apoptosis, but may significantly enhance the radiation‑induced apoptosis of A549 cells. Western blot analysis revealed that TLR9 activation by CpG ODN 7909 increased the levels of mitogen‑activated protein kinase 14, cellular tumor antigen p53, B‑cell lymphoma 2 associated X protein and genome polyprotein, and decreased Bcl‑2 expression levels, whereas these effects were not observed in CpG ODN 7909‑treated cells in which TLR9 was knocked down. These results suggest that CpG ODN 7909 may enhance radiosensitivity through TLR9 activation, and partially via the p53 pathway in A549 lung cancer cells.

View Figures

View References

1	Mutwiri G: TLR9 agonists: Immune mechanisms and therapeutic potential in domestic animals. Vet Immunol Immunopathol. 148:85–89. 2012. View Article : Google Scholar : PubMed/NCBI
2	Yoneda K, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Fuke H, Yamamoto N, Masuya M, Horie R, Uchida K and Takei Y: Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: Differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol. 33:929–936. 2008.PubMed/NCBI
3	He H, Genovese KJ, Swaggerty CL, Nisbet DJ and Kogut MH: Differential induction of nitric oxide, degranulation, and oxidative burst activities in response to microbial agonist stimulations in monocytes and heterophils from young commercial turkeys. Vet Immunol Immunopathol. 123:177–185. 2008. View Article : Google Scholar : PubMed/NCBI
4	Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S and Zhang R: Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther. 5:1585–1592. 2006. View Article : Google Scholar : PubMed/NCBI
5	Holtick U, Scheulen ME, von Bergwelt-Baildon MS and Weihrauch MR: Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs. 20:361–372. 2011. View Article : Google Scholar : PubMed/NCBI
6	Petrangolini G, Tortoreto M, Perego P, Carenini N, De Cesare M, Balsari A, Zunino F and Pratesi G: Combination of metronomic gimatecan and CpG oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther. 7:596–601. 2008. View Article : Google Scholar : PubMed/NCBI
7	Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, et al: Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res. 70:9816–9826. 2010. View Article : Google Scholar : PubMed/NCBI
8	Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T: Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
9	Wu HQ, Wang B, Zhu SK, Tian Y, Zhang JH and Wu HS: Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer. World J Gastroenterol. 17:996–1003. 2011.PubMed/NCBI
10	Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P, et al: Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 135:481–493. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, Wong LY, Klumpp DJ and Thumbikat P: The toll-like receptor pathway: A novel mechanism of infection induced carcinogenesis of prostate epithelial cells. Prostate. 68:223–229. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chang JH, Park JY and Kim SK: Dependence on p38 MAPK signalling in the up-regulation of TLR2, TLR4 and TLR9 gene expression in Trichomonas vaginalis-treated HeLa cells. Immunology. 118:164–170. 2006. View Article : Google Scholar : PubMed/NCBI
13	De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano D, Fuqua SA and Andò S: Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 25:3695–3707. 2011. View Article : Google Scholar : PubMed/NCBI
14	Riazantseva NV, Novitskiĭ VV, Kaĭgorodova EV, Chasovskikh NIu and Starikova EG: Mitogenactivated protein kinases JNK and p38 as redox-dependent molecular targets correction of programmed cell death disturbances in oxidative stress condition. Usp Fiziol Nauk. 40:3–11. 2009.(In Russian). PubMed/NCBI
15	Zha L, Qiao T, Yuan S and Lei L: Enhancement of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells. Cancer Biother Radiopharm. 25:165–170. 2010. View Article : Google Scholar : PubMed/NCBI
16	Yan L, Xu G, Qiao T, Chen W, Yuan S and Li X: CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of Toll-like receptor 9. Cancer Biother Radiopharm. 28:559–564. 2013. View Article : Google Scholar : PubMed/NCBI
17	Liu XQ, Qiao TK, Chen W and Yuan SJ: Role of ATM kinase in the effect of CpG-oligodeoxynucleotide-7909 on X-ray-induced G2/M phase arrest and apoptosis in A549 cells. Chin J Radiol Med Prot. 3:270–273. 2012.(In Chinese).
18	Viadiu H, Fronza G and Inga A: Structural studies on mechanisms to activate mutant p53. Subcell Biochem. 85:119–32. 2014. View Article : Google Scholar : PubMed/NCBI
19	Merino D and Malkin D: p53 and hereditary cancer. Subcell Biochem. 85:1–16. 2014. View Article : Google Scholar : PubMed/NCBI
20	Khan I, Garikapati KR, Shaik AB, Makani VKK, Rahim A, Shareef MA, Reddy VG, Pal-Bhadra M, Kamal A and Kumar CG: Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2-c] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis. Eur J Med Chem. 144:104–115. 2017. View Article : Google Scholar : PubMed/NCBI
21	Parvathaneni S, Lu X, Chaudhary R, Lal A, Madhusudan S and Sharma S: RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner. Oncotarget. 8:75924–75942. 2017. View Article : Google Scholar : PubMed/NCBI
22	Spring E and Holmberg P: Evaluation of experimental irradiation fractionation with the single-hit, multi-target model. Acta Radiol Ther Phys Biol. 7:297–306. 1968. View Article : Google Scholar : PubMed/NCBI
23	Yang L, Wu X, Wan M, Yu Y, Yu Y and Wang L: CpG oligodeoxynucleotides with double stem-loops show strong immunostimulatory activity. Int Immunopharmacol. 15:89–96. 2013. View Article : Google Scholar : PubMed/NCBI
24	Sommariva M, de Cesare M, Meini A, Cataldo A, Zaffaroni N, Tagliabue E and Balsari A: High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. J Transl Med. 11:252013. View Article : Google Scholar : PubMed/NCBI
25	Wang S, Liu X, Qiao T and Zhang Q: Radiosensitization by CpG ODN7909 in an epidermoid laryngeal carcinoma Hep-2 cell line. J Int Med Res. 45:2009–2022. 2017. View Article : Google Scholar : PubMed/NCBI
26	Sfondrini L, Sommariva M, Tortoreto M, Meini A, Piconese S, Calvaruso M, Van Rooijen N, Bonecchi R, Zaffaroni N, Colombo MP, et al: Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer. 133:383–393. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xing N, Qiao T, Zhuang X, Yuan S, Zhang Q and Xu G: CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells. Onco Targets Ther. 8:1443–1449. 2015. View Article : Google Scholar : PubMed/NCBI
28	Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, Ohba Y, Takaoka A, Yeh WC and Taniguchi T: Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA. 101:pp. 15416–15421. 2004; View Article : Google Scholar : PubMed/NCBI
29	Hong MY, Gao JL, Cui JZ, Wang KJ, Tian YX, Li R, Wang HT and Wang H: Effect of c-Jun NH₂-terminal kinase-mediated p53 expression on neuron autophagy following traumatic brain injury in rats. Chin Med J (Engl). 125:2019–2024. 2012.PubMed/NCBI
30	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
31	Strittmatter F, Gratzke C, Walther S, Göttinger J, Beckmann C, Roosen A, Schlenker B, Reich O, Stief CG and Hennenberg M: Alpha1-adrenoceptor signaling in the human prostate involves regulation of p38 mitogen-activated protein kinase. Urology. 78:969.e7–e13. 2011. View Article : Google Scholar
32	Aloni-Grinstein R, Schwartz D and Rotter V: Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J. 14:1392–1401. 1995.PubMed/NCBI
33	Liu R, Ji P, Liu B, Qiao H, Wang X, Zhou L, Deng T and Ba Y: Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. Oncol Lett. 13:1024–1030. 2017. View Article : Google Scholar : PubMed/NCBI
34	Wang P, Cui J, Wen J, Guo Y, Zhang L and Chen X: Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett. 12:4605–4612. 2016. View Article : Google Scholar : PubMed/NCBI
35	Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, Boeckers T, Debatin KM and Fulda S: Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia. 11:743–752. 2009. View Article : Google Scholar : PubMed/NCBI
36	Borges HL, Chao C, Xu Y, Linden R and Wang JY: Radiation-induced apoptosis in developing mouse retina exhibits dose-dependent requirement for ATM phosphorylation of p53. Cell Death Differ. 11:494–502. 2004. View Article : Google Scholar : PubMed/NCBI
37	Rossé T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B and Borner C: Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 391:496–499. 1998. View Article : Google Scholar : PubMed/NCBI
38	Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC and Reed JC: Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 423:456–461. 2003. View Article : Google Scholar : PubMed/NCBI
39	Arafat W, Zhou T, Naoum GE and Buchsbaum DJ: Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. J Egypt Natl Canc Inst. 27:205–215. 2015. View Article : Google Scholar : PubMed/NCBI
40	Torricelli C, Salvadori S, Valacchi G, Souček K, Slabáková E, Muscettola M, Volpi N and Maioli E: Alternative pathways of cancer cell death by rottlerin: Apoptosis versus autophagy. Evid Based Complement Alternat Med. 2012:9806582012. View Article : Google Scholar : PubMed/NCBI
41	Murphy M, Mabruk MJ, Lenane P, Liew A, McCann P, Buckley A, Billet P, Leader M, Kay E and Murphy GM: The expression of p53, p21, Bax and induction of apoptosis in normal volunteers in response to different doses of ultraviolet radiation. Br J Dermatol. 147:110–117. 2002. View Article : Google Scholar : PubMed/NCBI